KLK3 and cancer: In prostate cancer, the tissue architecture and the secretory pathway to the prostatic ducts are disrupted leading to increased leakage of PSA into extracellular fluid and circulation [10], [12], [49], but the expression of PSA is actually lower in cancer than in the normal prostate [50], [51].